Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | TNKS | O95271 | 6/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450694 | 0.92 | CCR5 (0.46) | CCR5TNKSGPR119CYP2C9CALCRL | |
| SCHEMBL20450695 | 0.92 | CCR5 (0.46) | CCR5TNKSGPR119CYP2C9CALCRL | |
| SCHEMBL31437335 | 0.90 | CYP2C9 (0.48) | CCR5TNKSTNKS2GPR119CYP2C9 | |
| SCHEMBL20450661 | 0.90 | CYP2C9 (0.48) | CCR5TNKSTNKS2GPR119CYP2C9 | |
| SCHEMBL18764531 | 0.90 | CYP2C9 (0.48) | CCR5TNKSTNKS2GPR119CYP2C9 | |
| SCHEMBL2247700 | 0.89 | CCR5 (0.51) | CCR5TNKSTNKS2GPR119CALCRL | |
| SCHEMBL16657347 | 0.84 | CCR5 (0.56) | CCR5 | |
| SCHEMBL16783378 | 0.80 | CCR5 (0.49) | CCR5KDM4ESPR | |
| SCHEMBL16652901 | 0.80 | HSD11B1 (0.50) | CCR5 | |
| SCHEMBL15289136 | 0.79 | TNKS (0.46) | TNKSTNKS2PIK3CASPRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328859-B1 | 3-((4-ISOQUINOLIN-3-YL)METHYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | BOEHRINGER INGELHEIM INT (DE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3328859-B1 | 3-((4-ISOQUINOLIN-3-YL)METHYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | BOEHRINGER INGELHEIM INT (DE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2019-01-03 | — | — | US | disclosed |
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| EP-2864323-B1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017018924-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2017-02-02 | — | — | WO | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | NR0B1, NR1I3, SCARB1 | CCR5 277/4885TNKS 4856/4885TNKS2 4839/4885 |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | CCR5 387/4885TNKS 1828/4885TNKS2 3371/4885 |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | CCR5 387/4885TNKS 1828/4885TNKS2 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.